BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33227576)

  • 1. Application of sulfoximines in medicinal chemistry from 2013 to 2020.
    Han Y; Xing K; Zhang J; Tong T; Shi Y; Cao H; Yu H; Zhang Y; Liu D; Zhao L
    Eur J Med Chem; 2021 Jan; 209():112885. PubMed ID: 33227576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery.
    Frings M; Bolm C; Blum A; Gnamm C
    Eur J Med Chem; 2017 Jan; 126():225-245. PubMed ID: 27821325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfoximines: a neglected opportunity in medicinal chemistry.
    Lücking U
    Angew Chem Int Ed Engl; 2013 Sep; 52(36):9399-408. PubMed ID: 23934828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfur Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry.
    Feng M; Tang B; Liang SH; Jiang X
    Curr Top Med Chem; 2016; 16(11):1200-16. PubMed ID: 26369815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
    Foote KM; Nissink JWM; McGuire T; Turner P; Guichard S; Yates JWT; Lau A; Blades K; Heathcote D; Odedra R; Wilkinson G; Wilson Z; Wood CM; Jewsbury PJ
    J Med Chem; 2018 Nov; 61(22):9889-9907. PubMed ID: 30346772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfoximines as potent RORγ inverse agonists.
    Ouvry G; Bihl F; Bouix-Peter C; Christin O; Defoin-Platel C; Deret S; Feret C; Froude D; Hacini-Rachinel F; Harris CS; Hervouet C; Lafitte G; Luzy AP; Musicki B; Orfila D; Parnet V; Pascau C; Pascau J; Pierre R; Raffin C; Rossio P; Spiesse D; Taquet N; Thoreau E; Vatinel R; Vial E; Hennequin LF
    Bioorg Med Chem Lett; 2018 May; 28(8):1269-1273. PubMed ID: 29571573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties.
    Boulard E; Zibulski V; Oertel L; Lienau P; Schäfer M; Ganzer U; Lücking U
    Chemistry; 2020 Apr; 26(19):4378-4388. PubMed ID: 31961028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.
    Sirvent JA; Lücking U
    ChemMedChem; 2017 Apr; 12(7):487-501. PubMed ID: 28221724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of tert-butyl isosteres: case studies of physicochemical and pharmacokinetic properties, efficacies, and activities.
    Westphal MV; Wolfstädter BT; Plancher JM; Gatfield J; Carreira EM
    ChemMedChem; 2015 Mar; 10(3):461-9. PubMed ID: 25630804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhodium-catalyzed direct synthesis of unprotected NH-sulfoximines from sulfoxides.
    Miao J; Richards NG; Ge H
    Chem Commun (Camb); 2014 Sep; 50(68):9687-9. PubMed ID: 25016917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron(II) triflate as an efficient catalyst for the imination of sulfoxides.
    Mancheño OG; Dallimore J; Plant A; Bolm C
    Org Lett; 2009 Jun; 11(11):2429-32. PubMed ID: 19473047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of Sulfoximine Carbamates by Rhodium-Catalyzed Nitrene Transfer of Carbamates to Sulfoxides.
    Zenzola M; Doran R; Luisi R; Bull JA
    J Org Chem; 2015 Jun; 80(12):6391-9. PubMed ID: 25989821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.
    Mäder P; Kattner L
    J Med Chem; 2020 Dec; 63(23):14243-14275. PubMed ID: 32870008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective.
    Lücking U
    Chemistry; 2022 Oct; 28(56):e202201993. PubMed ID: 35789054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Discovery of Macitentan - A Standard Medicinal Chemistry Program?
    Bolli MH
    Chimia (Aarau); 2017 Aug; 71(7):420-429. PubMed ID: 28779766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.
    Siemeister G; Lücking U; Wengner AM; Lienau P; Steinke W; Schatz C; Mumberg D; Ziegelbauer K
    Mol Cancer Ther; 2012 Oct; 11(10):2265-73. PubMed ID: 22821149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
    Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfoxaflor and the sulfoximine insecticides: chemistry, mode of action and basis for efficacy on resistant insects.
    Sparks TC; Watson GB; Loso MR; Geng C; Babcock JM; Thomas JD
    Pestic Biochem Physiol; 2013 Sep; 107(1):1-7. PubMed ID: 25149228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer.
    Lücking U; Jautelat R; Krüger M; Brumby T; Lienau P; Schäfer M; Briem H; Schulze J; Hillisch A; Reichel A; Wengner AM; Siemeister G
    ChemMedChem; 2013 Jul; 8(7):1067-85. PubMed ID: 23671017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expedition of in vitro dissolution and in vivo pharmacokinetic profiling of sulfur nanoparticles based antimicrobials.
    Choudhury SR; Basu A; Nag T; Sengupta K; Bhowmik M; Goswami A
    Environ Toxicol Pharmacol; 2013 Sep; 36(2):675-679. PubMed ID: 23892072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.